A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Summary

This phase 2, multicenter, two-part, open-label, single-arm study will be conducted in Japan and will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of pexidartinib in adult participants with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitation and not amenable to improvement with surgery.

Timeline

Start

2021-03-15

Primary completion

2023-03-20

Completion

2026-05-15

Drugs

Indications